Addex Therapeutics Ltd
ADXN
$7.10
-$0.2022-2.77%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -83.24% | -81.83% | -50.67% | -71.84% | -12.41% |
| Total Other Revenue | 205.88% | -- | 33.33% | 411.94% | -73.85% |
| Total Revenue | -81.89% | -81.87% | -50.47% | -66.63% | -13.37% |
| Cost of Revenue | -57.45% | 15.32% | 1.59% | -28.36% | -80.58% |
| Gross Profit | 7.55% | -165.12% | -104.39% | 15.24% | 92.48% |
| SG&A Expenses | -17.30% | -8.73% | 34.01% | -18.06% | -64.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.57% | -1.91% | 24.48% | -23.96% | -74.25% |
| Operating Income | 15.20% | -125.66% | -126.88% | 16.65% | 80.33% |
| Income Before Tax | -119.47% | -177.76% | -110.25% | 14.96% | 81.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -119.47% | -177.76% | -110.25% | 14.96% | 81.07% |
| Earnings from Discontinued Operations | 99.87% | 761.64% | -22.19% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.30% | 578.56% | -35.73% | 14.96% | 30.30% |
| EBIT | 15.20% | -125.66% | -126.88% | 16.65% | 80.33% |
| EBITDA | 22.20% | -98.90% | -127.86% | 15.78% | 80.04% |
| EPS Basic | 53.00% | 451.70% | 14.82% | 43.76% | 56.97% |
| Normalized Basic EPS | -72.31% | -104.00% | -31.71% | 43.75% | 88.31% |
| EPS Diluted | 40.97% | 427.09% | 14.82% | 43.76% | 55.84% |
| Normalized Diluted EPS | -72.31% | -20.00% | -31.71% | 43.75% | 88.31% |
| Average Basic Shares Outstanding | 27.20% | 36.18% | 59.24% | 51.40% | 61.72% |
| Average Diluted Shares Outstanding | 27.20% | 132.71% | 59.24% | 51.40% | 61.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
